This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR sensitive mutations.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-01.